ClinicalTrials.gg
Not yet recruitingNCT07574892RestartUpdated Sep 24, 2026

Reestablishing Normal Gut-brain Interaction in Anorexia Nervose With Normal Gut Microbiota

A Phase 1 interventional study of Psychotherapy as usual combined with single dose normal gut microbiota and Psychotherapy treatment as usual (TAU) in Anorexia Nervosa, sponsored by Haukeland University Hospital. Not yet recruiting at 4 sites in Norway. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Haukeland University Hospital · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

In this pilot study 36 patients with anorexia nervosa (AN) will be randomized to either treatment with psychotherapy as usual (TAU) or TAU plus fecal microbiota transplantation (FMT). The transplantation will be performed when refeeding has started. Patients randomized to TAU+FMT will choose either capsules or gastroscopy as source of FMT. One week after FMT gut microbiota will be collected and analyzed and compared with microbiota composition at baseline. The two groups are then followed during psychotherapy to assess whether it is feasible to give FMT during psychotherapy to study the effects on outcome. In addition, this pilot study is aiming at paving the way for performing larger studies to assess whether FMT improves outcome from psychotherapy when given in combination with psychotherapy in patients with AN.

Read the detailed description

Around fifty percent of the patients who enter psychotherapy for anorexia nervosa (AN) drop out from the psychotherapy. Nearly all patients who are unable to complete treatment have significant deterioration shortly after premature ending of psychotherapy. During the development of AN, the microbes in the gut are significantly altered probably due to malnutrition. Some studies indicate that these alterations in the composition of gut microbiota play a role in the maintenance of AN. In this study we are aiming at assessing the feasibility of combining psychotherapy with improvement of nutritional status with fecal microbiota transplantation (FMT). By improving the nutritional status of the patient before transplantation the transplant may have better survival with improved outcome. In this pilot study 36 patients who have at least one failed treatment attempt will be included. The transplantation will be performed when refeeding has started. Patients randomized to TAU+FMT will choose either capsules or gastroscopy as source of FMT. One week after FMT gut microbiota will be collected and analyzed and compared with microbiota composition at baseline. The two groups are then followed during psychotherapy to assess whether it is feasible to give FMT during psychotherapy to study the effects on outcome. In addition, this pilot study is aiming at paving the way for performing larger studies to assess whether FMT improves outcome from psychotherapy when given in combination with psychotherapy in patients with AN.

02

Conditions studied

  • Anorexia Nervosa

Browse trials for

Keywords

  • Anorexia nervosa
  • Fecal microbiota transplantation
  • Psychotherapy
03

In context

Anorexia Nervosa

469 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

This study's planned enrollment of 36 is below the median of 46 across 313 interventional studies indexed under Anorexia Nervosa.

Browse Anorexia Nervosa studies →

Lead sponsor

Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18 years or more Starting outpatient psychotherapy for anorexia nervosa At least one failed qualified treatment attempt

Exclusion criteria

Exclusion Criteria:

Age below 18 years below 16 kg/m2 Significant electrolyte disturbances Other signs of medical instability Presence of systemic disease, Immune deficiency Treated with immune-modulating medication Pregnancy Planning pregnancy Lactations Having undergone abdominal surgery (with the exception of appendectomy, cholecystectomy, caesarian section and hysterectomy) severe psychiatric disease (except anorexia nervosa) Use of probiotics or treatment with antibiotics within 8 weeks prior to study entry.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Psychotherapy treatment as usual (TAU)

    The 18 patient with anorexia nervosa randomized to this arm will receive treatment with psychotherapy for anorexia nervosa as usual (TAU)

    Other: Psychotherapy treatment as usual (TAU)

  • Experimental
    Patients receiving TAU in combination with FMT

    The 18 patient with anorexia nervosa randomized to this arm will receive treatment with psychotherapy for anorexia nervosa as usual (TAU) in combination with a single dose fecal microbiota transplantation (FMT)

    Biological: Psychotherapy as usual combined with single dose normal gut microbiota

Interventions

  • BiologicalPsychotherapy as usual combined with single dose normal gut microbiota

    Psychotherapy treatment as usual (TAU) combined with single dose normal fecal microbiota (FMT) will be compared with TAU

  • OtherPsychotherapy treatment as usual (TAU)

    Psychotherapy treatment as usual (TAU)

06

What researchers measure

Primary outcomes

  1. Feasibility of performing treatment with psychotherapy as usual (TAU) in combination with a single dose of fecal microbiota transplantation

    A single dose of fecal microbiota transplantation will be administered when the patients has established a nutritional status allowing survival of the transplant. Then the patients will be followed to the end of psychotherapy. Assessments will include description of gut microbiota composition and questionnaires describing the clinical course of the eating disorder.

    Time frame: 1 year

Secondary outcomes

  1. Body mass index (BMI)

    Body mass index to assess weight development

    Time frame: 1 year

  2. Eating disorder evaluation quesionnaire (EDE-Q) score

    Global score of the EDE-Q score will be used to assess eating disorder symptom severity

    Time frame: 1 year

  3. Clinical impairment assessment questionnaire (CIA)

    CIA will be used to assess the degree of influence on every life of the patient

    Time frame: 1 year

  4. ROME 4

    The patients will be assessed for the presence of ROME 4 criteria for functional gastrointestinal disorders including irritable bowel syndrome

    Time frame: 1 year

  5. Irritable bowel syndrome symptome severity score (IBS-SSS)

    IBS-SSS is used to assess the intensity of IBS symptoms

    Time frame: 1 year

  6. Gastrointestinal symptom rating scale for IBS (GSRS-IBS)

    GSRS-IBS will be used to assess the gastrointestinal symptoms of IBS

    Time frame: 1 year

  7. Fecal microbiota composition

    The composition of gut microbiota will be assessed when the patient has started psychotherapy and has estaliblished regular eating. In addition, composition of gut microbiota will be assessed one week after fecal microbiota transplantation

    Time frame: 1 week

07

Study locations

4 sites
  • Haugalandet distriktspsykiatriske senter
    Haugesund, Haugesund 5535, Norway
  • Helse Møre og Romsdal
    Ålesund, Møre og Romsdal 6026, Norway
  • Haukeland University Hospital in Helse Bergen
    Bergen, Norway 5096, Norway
  • Sola distriktspsykiatriske senter
    Stavanger, Sola 4050, Norway
08

References and documents

Publications

  • Panah FM, Stoving RK, Sjogren M, Micali N, Maschek S, Reis KD, Mirsepasi-Lauridsen HC, Petersen AM, Nielsen DS, Helms M, Rasmussen MA, Barfod KK. Impact of a single fecal microbiome transplantation in adult women with anorexia nervosa: an open-label feasibility pilot trial. Nat Commun. 2026 Jan 14;17(1):1747. doi: 10.1038/s41467-026-68455-8. PubMed 41535289 ↗
  • Frostad S. Are the Effects of Malnutrition on the Gut Microbiota-Brain Axis the Core Pathologies of Anorexia Nervosa? Microorganisms. 2022 Jul 24;10(8):1486. doi: 10.3390/microorganisms10081486. PubMed 35893544 ↗

Individual participant data

Plan to share: Yes — Aggregated, deidentified data

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: November 1st 2028 and for five years thereafter

Access criteria: Contact with principal investigator

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 8, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07574892
Collaborators
The Dam Foundation
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 24, 2026

Study contacts

Stein Frostad, MD PhD
Contact
stein.frostad@helse-bergen.no
+47 95003257
Olivia B Helland, Master of Science
Contact
olivia.bysheim.helland@helse-bergen.no

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion